Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1980 Jun;77(6):3725–3728. doi: 10.1073/pnas.77.6.3725

Interaction of pergolide with central dopaminergic receptors.

M Goldstein, A Lieberman, J Y Lew, T Asano, M R Rosenfeld, M H Makman
PMCID: PMC349691  PMID: 6932044

Abstract

The activity of pergolide, an N-propylergoline derivative, has been tested for stimulation of central dopaminergic receptors. Binding to dopamine receptors shows that pergolide acts as an agonist with respect to these receptors. GTP decreases the potencies of dopamine agonists and of pergolide, but not of bromocriptine, to displace [3H]spiroperidol ([3H]Spi) from striatal membrane sites. The GTP-sensitive site labeled by [3H]Spi seems to be localized on intrastriatal dopamine receptors. The potency of dopamine agonists and of pergolide to displace [3H]Spi from striatal receptor sites is reduced in membranes exposed to higher temperatures. Pergolide, but not hitherto-tested dopaminergic ergots, stimulates dopamine-sensitive adenylate cyclase in striatal homogenates. Thus, pergolide, unlike other dopaminergic ergots, acts as an agonist on GTP-sensitive components of [3H]Spi binding and stimulates dopamine receptors linked to dopamine-sensitive adenylate cyclase. The drug also induces turning behavior in rats with 6-OH-dopamine lesions and relieves tremor in monkeys with ventromedial tegmental lesions for a longer time at a lower dose than other tested dopaminergic ergots. Other studies have shown that it is effective in the treatment of patients with advanced parkinsonism.

Full text

PDF
3725

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown J. H., Makman M. H. Influence of neuroleptic drugs and apomorphine on dopamine-sensitive adenylate cyclase of retina. J Neurochem. 1973 Aug;21(2):477–479. doi: 10.1111/j.1471-4159.1973.tb04268.x. [DOI] [PubMed] [Google Scholar]
  2. Burt D. R., Creese I., Snyder S. H. Properties of [3H]haloperidol and [3H]dopamine binding associated with dopamine receptors in calf brain membranes. Mol Pharmacol. 1976 Sep;12(5):800–812. [PubMed] [Google Scholar]
  3. Calne D. B., Teychenne P. F., Leigh P. N., Bamji A. N., Greenacre J. K. Treatment of parkinsonism with bromocriptine. Lancet. 1974 Dec 7;2(7893):1355–1356. doi: 10.1016/s0140-6736(74)92219-3. [DOI] [PubMed] [Google Scholar]
  4. Fuller R. W., Clemens J. A., Kornfeld E. C., Snoddy H. D., Smalstig E. B., Bach N. J. Effects of (8beta)-8-[methylthio)methyl]-6-propylergoline on dopaminergic function and brain dopamine turnover in rats. Life Sci. 1979 Jan 22;24(4):375–382. doi: 10.1016/0024-3205(79)90334-5. [DOI] [PubMed] [Google Scholar]
  5. Fuxe K., Fredholm B. B., Ogren S. O., Agnati L. F., Hökfelt T., Gustafsson J. A. Ergot drugs and central monoaminergic mechanisms: a histochemical, biochemical and behavioral analysis. Fed Proc. 1978 Jun;37(8):2181–2191. [PubMed] [Google Scholar]
  6. Goldstein M., Battista A. F., Ohmoto T., Anagnoste B., Fuxe K. Tremor and involuntary movements in monkeys: effect of L-dopa and of a dopamine receptor stimulating agent. Science. 1973 Feb 23;179(4075):816–817. doi: 10.1126/science.179.4075.816. [DOI] [PubMed] [Google Scholar]
  7. Kartzinel R., TEYCHENNE P., Gillespie M. M., Perlow M., Gielen A. C., Sadowsky D. A., Calne D. B. Bromocriptine and levodopa (with or without carbidopa) in parkinsonism. Lancet. 1976 Aug 7;2(7980):272–275. doi: 10.1016/s0140-6736(76)90728-5. [DOI] [PubMed] [Google Scholar]
  8. Kebabian J. W., Calne D. B., Kebabian P. R. Lergotrile mesylate: an in vivo dopamine agonist which blocks dopamine receptors in vitro. Commun Psychopharmacol. 1977;1(4):311–318. [PubMed] [Google Scholar]
  9. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  10. Lemberger L., Crabtree R. E. Pharmacologic effects in man of a potent, long-acting dopamine receptor agonist. Science. 1979 Sep 14;205(4411):1151–1153. doi: 10.1126/science.382359. [DOI] [PubMed] [Google Scholar]
  11. Lew J. Y., Goldstein M. Dopamine receptor binding for agonists and antagonists in thermal exposed membranes. Eur J Pharmacol. 1979 May 15;55(4):429–430. doi: 10.1016/0014-2999(79)90121-3. [DOI] [PubMed] [Google Scholar]
  12. Lew J. Y., Nakamura S., Battista A. F., Goldstein M. Dopamine agonist potencies of ergolines. Commun Psychopharmacol. 1979;3(3):179–183. [PubMed] [Google Scholar]
  13. Lieberman A. N., Leibowitz M., Neophytides A., Kupersmith M., Mehl S., Kleinberg D., Serby M., Goldstein M. Pergolide and lisuride for Parkinson's disease. Lancet. 1979 Nov 24;2(8152):1129–1130. doi: 10.1016/s0140-6736(79)92524-8. [DOI] [PubMed] [Google Scholar]
  14. Lieberman A., Kupersmith M., Estey E., Goldstein M. Treatment of parkinson's disease with bromocriptine. N Engl J Med. 1976 Dec 16;295(25):1400–1404. doi: 10.1056/NEJM197612162952504. [DOI] [PubMed] [Google Scholar]
  15. Lieberman A., Miyamoto T., Battista A. F., Goldstein M. Studies on the antiparkinsonism efficacy of lergotrile. Neurology. 1975 May;25(5):459–462. doi: 10.1212/wnl.25.5.459. [DOI] [PubMed] [Google Scholar]
  16. Ludin H. P., Bass-Verrey F. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor. J Neural Transm. 1976;38(3-4):249–258. doi: 10.1007/BF01249442. [DOI] [PubMed] [Google Scholar]
  17. Markstein R., Herrling P. L. The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism. J Neurochem. 1978 Nov;31(5):1163–1172. doi: 10.1111/j.1471-4159.1978.tb06240.x. [DOI] [PubMed] [Google Scholar]
  18. Marsden C. D., Parkes J. D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet. 1977 Feb 12;1(8007):345–349. doi: 10.1016/s0140-6736(77)91146-1. [DOI] [PubMed] [Google Scholar]
  19. Mishra R. K., Gardner E. L., Katzman R., Makman M. H. Enhancement of dopamine-stimulated adenylate cyclase activity in rat caudate after lesions in substantia nigra: evidence for denervation supersensitivity. Proc Natl Acad Sci U S A. 1974 Oct;71(10):3883–3887. doi: 10.1073/pnas.71.10.3883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nakamura S., Engel J., Goldstein M. Blockade of lergotrile or apomorphine induced turning behavior by haloperidol and clozapine. Commun Psychopharmacol. 1978;2(3):185–190. [PubMed] [Google Scholar]
  21. POIRIER L. J., SOURKES T. L. INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM. Brain. 1965 Mar;88:181–192. doi: 10.1093/brain/88.1.181. [DOI] [PubMed] [Google Scholar]
  22. Schwarcz R., Creese I., Coyle J. T., Snyder S. H. Dopamine receptors localised on cerebral cortical afferents to rat corpus striatum. Nature. 1978 Feb 23;271(5647):766–768. doi: 10.1038/271766a0. [DOI] [PubMed] [Google Scholar]
  23. Zahniser N. R., Molinoff P. B. Effect of guanine nucleotides on striatal dopamine receptors. Nature. 1978 Oct 5;275(5679):453–455. doi: 10.1038/275453a0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES